Can I Take Tirzepatide: Eligibility & Biomarker Context

Last reviewed: May 30, 2026

Last updated: May 30, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Yes, many people can take tirzepatide—but eligibility depends on specific clinical criteria, medical history, and metabolic factors. Tirzepatide is a GLP-1 receptor agonist and GIP receptor agonist approved for type 2 diabetes and weight management, with clinical trials demonstrating A1C reductions of 2.2–2.8% and weight loss of 21–22% in non-diabetic adults.

Determining if tirzepatide is right for you requires careful provider evaluation. PlexusDx supports this decision-making process through compounded tirzepatide options and precision wellness assessment tools that can provide context about your individual metabolic and genetic profile.

Clinical Eligibility Criteria for Tirzepatide Therapy

Tirzepatide candidacy typically requires documented type 2 diabetes or obesity (BMI ≥27 kg/m² with weight-related comorbidities, or BMI ≥30 kg/m²). Your provider will evaluate baseline A1C, kidney function, liver function, and cardiovascular history. Age, pregnancy status, and history of medullary thyroid cancer are also important screening factors.

Kidney function matters significantly: tirzepatide can be used with mild to moderate renal impairment, but dose adjustment may be needed. Cardiovascular risk and prior hypersensitivity to GLP-1 compounds influence eligibility. A comprehensive medical review ensures tirzepatide fits your specific clinical picture.

Metabolic Markers and Biomarker Context in Tirzepatide Selection

Beyond basic eligibility, biomarkers like fasting glucose, insulin levels, inflammatory markers (hsCRP), and lipid profiles provide context about your metabolic state. High baseline insulin resistance, elevated triglycerides, or inflammatory markers may inform how tirzepatide works in your individual case. Baseline kidney function (eGFR, urine albumin) and liver enzymes guide safety monitoring.

Biomarker	Clinical Relevance for Tirzepatide
Fasting Glucose	Indicates baseline glycemic control; tirzepatide effectiveness varies by baseline A1C
Kidney Function (eGFR)	Determines dose appropriateness; tirzepatide requires monitoring with eGFR <45
Lipid Panel	Elevated triglycerides may improve with tirzepatide; baseline assessment informs monitoring
Liver Function	AST/ALT baseline guides safety; tirzepatide use generally safe with mild hepatic impairment
BMI & Body Composition	Baseline BMI and lean vs. fat mass inform expected weight loss trajectory and dosing

Genetic Predisposition and Personalized Tirzepatide Response

Genetic variants in GLP-1 receptor (GLP1R rs6923761), GIP receptor (GIPR rs1800437), and metabolic genes (FTO rs9939609, MC4R rs17782313) may provide context about how your body responds to tirzepatide. These variants are associated with appetite regulation, weight loss magnitude, and metabolic flexibility in some populations.

The PlexusDx Precision Peptide Genetic Test reveals predispositions in these peptide pathways. This information may help provide context for your provider conversation about whether tirzepatide is a logical fit for your metabolic profile. Genetic context does not predict exact medication response but can support more personalized discussion.

Safety Monitoring and Who Should Avoid Tirzepatide

Tirzepatide is not appropriate for individuals with personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, or severe hypersensitivity to tirzepatide or other GLP-1 compounds. Pregnancy and breastfeeding are contraindications; women of childbearing age should use contraception during therapy and for 4 weeks after discontinuation.

Common side effects include nausea, vomiting, and diarrhea, typically mild-to-moderate and often diminishing over weeks. Rare but serious risks include pancreatitis, gallbladder disease, and diabetic retinopathy changes. Ongoing provider monitoring—including quarterly kidney function, lipids, and clinical assessment—ensures safety throughout treatment.

How PlexusDx Supports a More Personalized Approach

PlexusDx integrates biomarker assessment and genetic context to support your conversation with your healthcare provider about tirzepatide eligibility. Our Precision Peptide Genetic Test screens for predispositions in GLP1R, GIPR, FTO, and MC4R variants—key genes influencing peptide pathway responsiveness and metabolic adaptation. This information may help provide clinical context for personalized tirzepatide evaluation.

The genetic test reveals predispositions in peptide signaling pathways, not exact medication response. For example, certain GLP1R or GIPR variants are associated with differential appetite suppression or weight loss magnitude in research populations. Combined with your biomarker profile and medical history, this context supports a more informed provider discussion about whether tirzepatide aligns with your metabolic needs.

PlexusDx offers compounded tirzepatide injection ($229–$309/mo) and oral tirzepatide ($229–$509/mo) from licensed 503A compounding pharmacies. Alongside our Precision Peptide Genetic Test ($99 add-on or $298 standalone), you gain personalized context to discuss with your provider. A qualified healthcare provider should interpret all genetic and biomarker findings before starting any tirzepatide therapy.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral starts at $229-$509/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.